Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: greedsgd_2000 who wrote (1767)	9/29/2000 4:54:10 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 52153

greedsgd <<1. Wall St Journal front page-left- Sept 28 article referring to small study at Mass General Hospital - with the conclusion that an Immune based strategy may now be possible against HIV. The article fails to mention HEPH in any way, which seems odd as they are probably one of the few focusing on this immune based approach.>> If its the article I remember, the reported approach depends on virtually immediate shock treatment with existing therapies after infection, then total withdrawal. HEPH's product is designed to tilt the immune system back in favor of the previously depleted helper T-cells using a novel molecule. So the two are related only in disease, but not otherwise. The new hires are interesting. Thank you. I am trying to read the poster from the So African conference (I've never seen a smaller font) and if I think of anything interesting I'll post over at HEPH. Wilder

To: greedsgd_2000 who wrote (1767)	9/30/2000 11:59:06 AM
From: Biomaven	Respond to of 52153

<<HEPH>> HEPH is clearly becoming more respectable in terms of their personnel and their explanations for why their stuff might work. However, remember they started at what looked like near-scam levels on both these counts. Their science is still non-mainstream - doesn't mean it's wrong, just that they have a higher burden of proof, which I don't think they have yet met. (NYMX is a good exemplar of a company with very big claims that the street clearly doesn't believe in the slightest). Bottom line here: interesting, but lots of caution flags still flying. I'm still staying away for now. Peter